Literature DB >> 7558454

Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients.

M R Teixeira1, N Pandis, G Bardi, J A Andersen, F Mitelman, S Heim.   

Abstract

Intratumor phenotypic heterogeneity is one of the characteristics of breast carcinomas, and genetic mechanisms are likely to contribute to it. We have studied breast cancer clonal heterogeneity by cytogenetic analysis of multiple tumor samples (one from each tumor quadrant) as well as samples of macroscopically normal surrounding breast tissue from 3 patients with this disease. Clonal chromosome aberrations were found in all 8 successfully analyzed samples from the carcinomas. Two to 6 cytogenetically unrelated clones were detected in each case, unevenly distributed among the tumor quadrants. Karyotypic abnormalities were also found in 4 out of 9 macroscopically tumor-free samples from the surrounding tissue; in 2 of these samples, a ductal carcinoma in situ was detected histologically, and the cytogenetic evidence suggests that the remaining 2 samples also contained neoplastic cells. Quantitative analysis of the findings revealed a statistically significant higher frequency of karyotypically abnormal cells in samples with a histologic diagnosis of carcinoma vs. samples without any detected malignancy. That cells bearing cytogenetic evidence that they belong to the tumor parenchyma are left behind during breast-conserving surgery for carcinoma of the breast may account for the relatively high long-term local relapse rates seen in this disease.

Entities:  

Mesh:

Year:  1995        PMID: 7558454     DOI: 10.1002/ijc.2910630113

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

3.  [The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis].

Authors:  H Bürger; C Kersting; D Hungermann; T Decker; W Böcker
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

Review 4.  Evolution of the cancer genome.

Authors:  Ondrej Podlaha; Markus Riester; Subhajyoti De; Franziska Michor
Journal:  Trends Genet       Date:  2012-02-16       Impact factor: 11.639

5.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

6.  Genetically abnormal clones in histologically normal breast tissue.

Authors:  P S Larson; A de las Morenas; L A Cupples; K Huang; C L Rosenberg
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

Review 7.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

Review 8.  Culture models of human mammary epithelial cell transformation.

Authors:  M R Stampfer; P Yaswen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 9.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

Review 10.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.